6/22/2009 | DD | AtheroGenics out of bankruptcy; trustee to make plan distributions
|
6/16/2009 | DD | AtheroGenics' net loss improves to $364,317 in May on zero revenues
|
6/9/2009 | DD | AtheroGenics liquidation plan approved
|
6/2/2009 | DD | AtheroGenics confirmation hearing ends with plan taken under advisement
|
5/20/2009 | DD | AtheroGenics reports operating loss shrinks to $1.44 million in April
|
4/20/2009 | DD | AtheroGenics posts $1.5 million operating loss, no revenues in March
|
4/15/2009 | DD | AtheroGenics' plan-vote solicitation exclusivity extended to June 12
|
4/15/2009 | DD | AtheroGenics disclosure statement OK'd; confirmation hearing June 2
|
3/27/2009 | DD | AtheroGenics $2 million non-cash asset sale approved
|
3/27/2009 | DD | AtheroGenics requests two-month extension to exclusive plan-solicitation period
|
3/20/2009 | DD | AtheroGenics posts $1.11 million February operating loss
|
3/17/2009 | DD | AtheroGenics non-cash asset sale procedures approved
|
3/12/2009 | DD | AtheroGenics sets bid procedures for sale of non-cash assets
|
2/19/2009 | DD | AtheroGenics reports $1.06 million January operating loss
|
2/12/2009 | DD | AtheroGenics files plan of reorganization
|
1/22/2009 | DD | AtheroGenics initial purchase offer deadline passes; debt to exceed proceeds, cash on hand
|
1/20/2009 | DD | AtheroGenics records $1.27 million December operating loss
|
12/18/2008 | DD | AtheroGenics posts $1.17 million November operating loss
|
12/3/2008 | DD | AtheroGenics posts $1.32 million October operating loss
|
11/17/2008 | DD | AtheroGenics records $7.47 million third-quarter operating loss
|
10/17/2008 | DD | AtheroGenics unsecured creditors committee appointed
|
10/7/2008 | CVDD | AtheroGenics agrees to convert case to Chapter 11, plans to sell assets
|
9/23/2008 | DD | AtheroGenics reduces workforce by 40%
|
9/16/2008 | CVDDSS | AtheroGenics noteholders file involuntary Chapter 7 bankruptcy petition
|
9/2/2008 | CVDDSS | AtheroGenics to skip note payments, evaluate restructuring alternatives; noteholder proposal rejected
|
8/20/2008 | CVDDSS | AtheroGenics considering exchange of 4.5% convertible notes
|
8/11/2008 | CVDDSS | AtheroGenics considers bankruptcy as one convertible repayment option
|
5/9/2008 | CVDDSS | AtheroGenics 4.5% convertibles repayment to leave company short of cash for 2009
|
1/9/2008 | CV | AtheroGenics extends maturity profile by restructuring $17.5 million of 4.5% convertibles
|
11/26/2007 | CV | Market Commentary: Countrywide, Fannie Mae, E*Trade down as financials tumble; SunPower, Suntech Power brighten dark day
|
11/12/2007 | CV | Market Commentary: E*Trade shellacked; AtheroGenics whacked; Suntech, SunPower smacked; AMR, Continental soar
|
6/25/2007 | CV | AtheroGenics exchanges for 4.5% convertibles
|
6/22/2007 | CV | AtheroGenics plans exchange for 4.5% convertibles
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
3/28/2007 | CV | Market Commentary: Beazer firm on probe; AtheroGenics falls on reports; Equinix gains, Kilroy flat on debuts; five deals launch
|
3/27/2007 | CV | Market Commentary: CV Therapeutics, AtheroGenics gain on data; Equinix higher, Kilroy quiet in gray
|
3/19/2007 | CV | Market Commentary: AtheroGenics falls; Host Hotels, Freeport-McMoran up in gray; ProLogis, ViroPharma, Pioneer plan deals
|
3/19/2007 | SS | Market Commentary: EGL, Triad up on higher offers; Take-Two better; Acadia zooms; Todco drives drillers; lenders off
|
1/31/2007 | SS | Market Commentary: Altria, Kraft players cheer, exit; Bristol-Myers speculation widens; Google gyrates; Delta Air dives
|
1/3/2007 | SS | Market Commentary: Oil stocks plunge; AtheroGenics bulls raging; Nvidia sinks; Doral falls; Applica up; Home Depot better
|
10/24/2006 | BT | AtheroGenics lowers 2006 guidance for net cash use by $5 million, reports $10.3 million in Q3 revenue
|
7/20/2006 | BT | AtheroGenics reports second-quarter revenue of $6.3 million, net loss of $0.33 per share
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
4/20/2006 | BT | AtheroGenics says Q1 net loss reaches $19.2 million
|
2/2/2006 | BT | AtheroGenics, Astellas extend collaboration for organ transplant rejection agent
|
1/30/2006 | BT | AtheroGenics, AstraZeneca waiting period ends for license; AtheroGenics to get $50 million payment
|
1/11/2006 | BTCV | AtheroGenics exchanges $14 million 4.5% convertibles for stock
|
12/23/2005 | BT | Market Commentary: Progenics, Wyeth rise on $416.5 million pact; Par Pharma higher; AtheroGenics gains further 7%
|
12/22/2005 | BT | AtheroGenics signs licensing deal with AstraZeneca for atherosclerosis drug worth up to $1 billion
|
12/22/2005 | BT | Market Commentary: AtheroGenics zooms on $1 billion pact with AstraZeneca; Regeneron rises 6%; BioCryst bounces 16%
|
12/22/2005 | CV | Market Commentary: Cephalon convertibles gain on patent agreement; SFBC up on possible sale; Albertson's, Placer lose
|
12/13/2005 | BTCV | New Issue: Lehman prices $12.5 million Yeelds linked to AtheroGenics
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
10/4/2005 | BT | Market Commentary: CancerVax crashes; Serono slips; Protein Design Labs cheered; Celgene off; Keryx up
|
8/29/2005 | BT | Market Commentary: AtheroGenics, Amylin Pharma, Alpharma extend gains on takeover chatter; Pfizer, Merck credit mixed
|
8/26/2005 | CV | Market Commentary: DOV Pharmaceutical convertibles tumble; Atherogenics adds; Agilent active on call news
|
8/26/2005 | BT | Market Commentary: AtheroGenics joins Amylin in gains linked to takeover chatter; Isis easier; DOV Pharma dives
|
1/12/2005 | CV | AtheroGenics greenshoe exercised, raising convertibles to $200 million
|
1/7/2005 | CV | Market Commentary: AtheroGenics ends at 100.5; Western Wireless steady; Cap Gemini pressures techs
|
1/7/2005 | CV | New Issue: AtheroGenics sells upsized $175 million convertible to yield 1.5%, up 35%
|
1/6/2005 | CV | Market Commentary: Western Wireless comes in on Alltel deal buzz; Citizens gains; Leucadia off; AtheroGenics up
|
1/5/2005 | CV | AtheroGenics $125 million convertible talked to yield 1.5%-2.0%, up 30%-35%
|
1/5/2005 | CV | Market Commentary: Celanese, AtheroGenics talk emerges; Delta cuts fares but convertibles quiet; OMI firmer
|
10/5/2004 | CV | Market Commentary: General Mills issue rises; Chiron, Henry Schein fall on flu scare but MedImmune gains
|
9/28/2004 | CV | Market Commentary: Human Genome up 1.5 in gray on tighter talk; Calpine, American Financial issues up; Lions Gate emerges
|
9/27/2004 | CV | Market Commentary: Human Genome, American Financial deals emerge; new Calpine issue quiet; AtheroGenics soars after-hours
|
12/8/2003 | CV | Market Commentary: Issuers unwrap $1.73 billion of new paper and more set to come this week, this month
|
8/19/2003 | CV | AtheroGenics greenshoe exercised, raising convertibles to $100 million
|
8/14/2003 | CV | New Issue: AtheroGenics sells upsized $80 million convertible at 4.5%, up 22.5%
|
8/13/2003 | CV | Market Commentary: New deal train chugs slowly along with string of small deals; dividend risk still high profile
|
8/12/2003 | CV | AtheroGenics plans $75 million convertible offering
|